For any questions relating to the Annual Conference, please contact the conference office below:
Wheldon Events & Conferences
93 Watling Street, Bridgtown,
Cannock, Staffordshire WS11 0BG
T: +44 (0) 1543 503 322
F: +44 (0) 1543 466 890
"...As a current medical student undertaking a summer research project investigating the barriers associated with the implementation of familial hypercholesterolaemia in Scotland, I found the conference both enjoyable and incredibly helpful to see how these problems are being addressed not just in Scotland but across the world. The conference also allowed me to present a poster to an audience of experts in the field of lipidology, and despite not winning any awards it was a fantastic learning opportunity... I am confident that the experience I gained will benefit both my project and my future medical career."
Abstracts of Free Communications
– Poster Session
Friday 7 July 2017
08:45 - 09:45
Deadline for travel grant applications: CLOSED
Judging panel: Elizabeth HUGHES, Alan REES, Peter SEVER
EXPLORING DIGITAL ARTS-BASED APPROACHES THAT EMPOWER CHILDREN AND YOUNG PEOPLE WITH FAMILIAL HYPERCHOLESTEROLAEMIA (FH)
Ashfield-Watt P1*, Philips A2, Dale P3, Hale M4 and McDowell I5
1Division of Population Health, School of Medicine, Cardiff University, CF14 4XN. 2Independent videographer. 3Aneurin Bevan University Health Board. 4Cardiff and Vale University Health Board. 5Centre for Medical Education, School of Medicine, Cardiff University, CF14 4XN.
SHARING EXPERIENCE: FIRST PATIENT IN THE UK TO RECEIVE LOMITAPIDE THERAPY
Cegla J, Walji S, Neuwirth C, Barton L, Thompson G, Scott J
Hammersmith Hospital Lipid Clinic, Imperial College Healthcare NHS Trust, UK
STANDARDISING GENETIC VARIANT CLASSIFICATION FOR FH - APPLICATION OF THE ACMG GUIDELINES
Dent C*1, Hills A1, Honeychurch J1, Watson E1, Dean P1, Woodward G1, Wadsley M1, Davies J1, Yarram-Smith L1, Humphries S2, Leigh S2, Haralambos K3, Bayly G4, Williams M1
1 Bristol Genetics Laboratory, Bristol, UK
2 Centre for Cardiovascular Genetics, UCL, London, UK
3 University Hospital of Wales, Cardiff, UK
4 Department of Biochemistry, Bristol Royal Infirmary, UK
DEVELOPMENT OF A MULTIGENE PANEL SCREENING TEST FOR HYPERTRIGLYCERIDAEMA USING NEXT GENERATION SEQUENCING
Downie P1, Honeychurch J2, Dean P2, Whittington R2, Woodward G2, Moore R2, Day A1, Williams M2, Bayly G1
1Department of Clinical Biochemistry, Bristol Royal Infirmary, Bristol, United Kingdom
2Bristol Genetics Laboratory, Southmead Hospital, Bristol, United Kingdom
UTILIZING AN AUTOMATED PATIENT CONTACT NOTIFICATION SERVICE / HIGH LDL ALERT SYSTEM - FOLLOWING SECONDARY CARE / HOSPITAL ATTENDANCE IN NORTH WALES (BETSI CADWALADR UNIVERISTY HEALTH BOARD) – A 12 MONTH REVIEW
*Gingell R (FH Specialist Nurse), Teoh YP (Consultant Chemical Pathologist), Shah M (Associate Specialist), Howard K (Genetics Specialist Nurse), Hussain H (Cardiology Registrar)
Betsi Cadwaladr University Health Board
HOW MANY PATIENTS WITH A MONOGENIC DIAGNOSIS OF FAMILIAL HYPERCHOLESTEROLEMIA ARE CURRENTLY KNOWN IN UK LIPID CLINICS?
Haralambos K1*, Payne J, Datta D, McDowell I, Cramb R, Williams S, Cather M, Neely D, Soran H, Miedzybroadzka Z, Whitmore J, Williams M, Humphries S
Haralambos K, Cardiff University, Cardiff, UK
Payne J, HEART UK, UK
Datta D, All Wales FH Cascade Testing Service, Cardiff, UK
McDowell I, Cardiff University, Cardiff, UK
Cramb R, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
Williams S, HEART UK, UK
Cather M, Northern Ireland Regional Genetics Service, Belfast, UK
Neely D, RDG, Newcastle Upon Tyne NHS Foundation Trust, Newcastle, UK
Soran H, University Department of Medicine, Central Manchester University Hospitals NHS, Manchester, UK Miedzybroadzka Z, University of Aberdeen Medical Genetics Group & NHS Grampian, Aberdeen, UK
Whitmore J, British Heart Foundation, London, UK
Williams M, Bristol Genetics Laboratory, Bristol, UK
Humphries S, Centre for Cardiovascular Genetics, UCL, London, UK
GENETIC AND PHENOTYPIC SPECTRUM OF HYPERTRIGLYCERIDAEMIA IN A LIPID CLINIC IN THE UK
N Hoshi, Anjly Jain, Trupti Kolvekar, Mahtab Sharifi, Devaki Nair
Clinical Biochemistry Department, Royal Free Hospital, London, UK
COST EFFECTIVENESS OF CASCADE TESTING FOR FAMILIAL HYPERCHOLESTEROLAEMIA, BASED ON DATA FROM FH SERVICES IN THE UK
Humphries SE1*, Pears R2, Miedzybrodzka Z3, Haralambos K4, Cather M5, Watson M6, Kerr M7
1 Institute of Cardiovascular Science, UCL London, 2 Hampshire County Council, Winchester, 3 U of Aberdeen, Scotland, 4 Wales Heart Research Institute, Cardiff University, 5 Northern Ireland Regional Genetics Centre ,Belfast,6 University Hospital Southampton, Southampton SO16 5YA, 7 Richmond, Surrey.
RESULTS OF THE INVESTIGATION OF FINDINGS AND OBSERVATIONS CAPTURED IN BURDEN OF ILLNESS SURVEY IN FCS PATIENTS (IN-FOCUS) STUDY: EUROPEAN RESPONDENTS
Davidson M1, Stevenson M2, Hsieh A2, Jones R2 Issa B3, Romeo S4, Witztum J5
1. Department of Medicine, University of Chicago, Chicago, IL, USA; 2. Akcea Therapeutics, Cambridge, MA, USA; 3. Department of Endocrinology, University Hospital of South Manchester, Wythenshawe, UK, 4. University of Gothenburg, Sahlgrenska Academy & Sahlgrenska University Hospital, Department of Cardiology, Gothenburg, Sweden, 5. Division of Endocrinology and Metabolism, University of California San Diego, La Jolla, CA, USA
AN AUDIT OF THE EFFECTIVENESS OF PCSK9 INHIBITION IN REDUCING CHOLESTEROL IN PATIENTS ATTENDING LIPID CLINICS
Kohli M1, McMahon Z1, Ramachandran R1, Crook MA1, Reynolds TM2, Wierzbicki AS1
1.Dept Metabolic Medicine, Guy’s & St Thomas’ Hospitals, London, UK
2. Dept Chemical Pathology, Queen’s Hospital, Burton-on-Trent
A Pottle*, M Barbir
Royal Brompton and Harefield NHS Foundation Trust, Harefield Hospital, London. UK
EFFECT OF PCSK9 INHIBITION WITH ALIROCUMAB ON LIPOPROTEIN (A) IN PATIENTS WITH HIGH RISK OF CARDIOVASCULAR DISEASE
Safdar S*, Cramb R, Dawson C.
Department of Clinical Biochemistry Queen Elizabeth Hospital Birmingham, UK
UNMODERATED POSTER SESSION:
INJECT AWAY: THE HAREFIELD EXPERIENCE ON DELIVERING THE NEW PCSK9 INHIBITORS
Browne C*, Neves E*, Breen J, Davies L, Priestley-Barnham L, Pottle A, Hayes C, Thompson K, Barbir M.
Royal Brompton & Harefield NHS Foundation Trust. Harefield Hospital Hill End Road Harefield UB9 6JH
IMPACT OF PCSK9 INHIBITORS ALIROCUMAB AND EVOLOCUMAB ON TOTAL & LDL CHOLESTEROL IN CLINICAL PRACTICE
Department of Clinical Biochemistry, The Shrewsbury and Telford Hospital NHS Trust, Princess Royal Hospital, Telford, UK
PAEDIATRIC FH, A MULTIDISCIPLINARY APPROACH; CHALLENGES, LESSONS LEARNT AND ACHIEVEMENTS
Cazeaux, A*, Sherman, CI, Davis NL
Clinical Genetics, G Level, Princess Anne Hospital, Coxford Road, Southampton. SO16 5YA
CLINICAL OUTCOMES FROM A TIER THREE WEIGHT MANAGEMENT SERVICE
Cordy HO*, Rouch K, Govier A, Adams O, Griffiths H, Singh S, Star L, Crossley L, Nicholls H, Datta DBN
Cardiff Weight Management Service, Cardiff and Vale University Health Board, Cardiff
THE ACUTE EFFECT OF A SINGLE SESSION OF LIPOPROTEIN APHERESIS ON CENTRAL HAEMODYNAMICS IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLAEMIA
EA Ellins1*, S Watkins2, DBN Datta2 DA Rees3 & JP Halcox1
1Institute of Life Sciences, Swansea University Medical School, 2Lipid Unit, University Hospital Llandough, 3School of Medicine, Cardiff University.
A CASE OF CHARCOT-MARIE-TOOTH (CMT) DISEASE WITH HYPERCHOLESTEROLAEMIA AND STATIN SIDE-EFFECT
Maghsoodi N (1,2), Crook M A (1,3)
(1) Department of Chemical Pathology, Guy’s and St Thomas’s Hospital, London, UK
(2) Department of Chemical Pathology, East Surrey Hospital, Redhill, UK
(3) Department of Clinical Biochemistry, Lewisham Hospital NHS Trust, London, UK
OPTIMISING SECONDARY CARDIOVASCULAR PREVENTION: A RETROSPECTIVE AUDIT ON STATIN PRESCRIBING IN AN INPATIENT COHORT PRESENTING WITH ACUTE CORONARY SYNDROME
Koulouroudias M1,2*, Manou-Stathopoulou S1,2*, Sivapackianathan R2 and Gunganah K2
1Joint first authors; 2Newham University Hospital, London, UK
A UNIQUE PHARMACIST LEAD LIPID CLINIC FOR THE SERVICE DELIVERY OF PCSK9 MONOCLONAL INHIBITOR THERAPY IN A TERTIARY REFERRAL CENTRE
YL Holloway1, Kamrudeen Mohammed2 and Deepa Narayanan3
1 Senior Pharmacist (Cardiology), Hull and East Yorkshire Hospitals NHS Trust 2 Consultant Physician, Diabetes and Endocrinology, Hull and East Yorkshire Hospitals NHS Trust 3 Consultant Chemical Pathology and metabolic medicine, Hull and East Yorkshire Hospitals NHS Trust
AN AUDIT ON THE USE OF PCSK9 MONOCLONAL INHIBITOR THERAPY IN LIPID CLINIC AT A TERTIARY REFERRAL CENTRE
Deepa Narayanan1*, YL Holloway2, Kamrudeen Mohammed3
1 Consultant Chemical Pathology and metabolic medicine, Hull and East Yorkshire Hospitals NHS Trust 2 Senior Pharmacist (Cardiology), Hull and East Yorkshire Hospitals NHS Trust 3 Consultant Physician, Diabetes and Endocrinology, Hull and East Yorkshire Hospitals NHS Trust
THE IMPACT OF LIPOPROTEIN LIPASE DEFICIENCY ON QUALITY OF LIFE: A DETAILED STRUCTURED QUALITATIVE STUDY
Neelamekam S *1,2, Kwok S1,2, Malone R3, Wierzbicki AS4, Soran H1,2
1 Cardiovascular Trial Unit, Central Manchester University Hospitals NHS Foundation Trust
2 Division of Cardiovascular Sciences, University of Manchester
3 Chiesi Limited, UK
4 Guy's and St Thomas' Hospitals, London
RESULTS OF LIPID LOWERING WITH STATINS IN PATIENTS FOLLOWING ACUTE CORONARY SYNDROME (ACS) IN A TERITIARY CENTRE
A Pottle*, J Bellchambers, S Deane, N Dent, F Eggenton, S Grigg, N Mackay, M Barbir, M Mason
Heart Division, Royal Brompton and Harefield NHS Foundation Trust, Harefield Hospital, London. UK
EFFICIENCY OF WELSH GENOTYPE SORING IN COST EFFECTIVE GENETIC TESTING FOR HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA
Safdar S, Cramb R, Dawson C.
Department of Clinical Biochemistry Queen Elizabeth Hospital Birmingham, UK
Poster Presentation Prizes - £150 and £75
Two prizes will be awarded for the best healthcare professional poster free communication made at the conference.
£150 – winner
£75 – runner up
Poster "People's Choice" Prize - £100 ** NEW **
One prize will be awarded for the best poster as nominated by conference delegates during the conference. This is your opportunity to vote for your "People's Choice" best poster. We would encourage delegates to attend during the moderated poster session on Friday morning when poster authors will be in attendance. A voting slip will be included in each delegate pack and votes can be made up until noon on Friday.
Every vote counts - please take time to view the posters.
Poster presentations will be marked by a judging panel on presentation and content.
Whilst authors must be on hand to discuss their work with the judging panel during this time the posters will be available for delegates to view throughout the conference period.
Presenting authors must be ready with 3-4 bullet points explaining their poster which will be followed by 2 minutes discussion with the judges.
Link to prize and award information
Presented moderated abstracts will be published after the conference on line in Atherosclerosis Supplements.
INFORMATION TO POSTER AUTHORS:
Poster board size:
1m (left to right) x 2m (top to bottom) – portrait - (100cm wide x 200cm deep)
THUS PLEASE ENSURE:
1. Your poster is printed to portrait and NOT landscape size.
2. That your poster is printed to A0 size (841mm wide x 1189 mm deep).
Velcro will be provided for your use. NO pins, blue-tak or cellotape can be used as these will damage the panels and you will be charged for any damage incurred.
You may erect your poster on Wednesday from 1500 hours.
Posters must be ready for viewing from 1900 hours.
Please refer to the allocated board number as detailed within the programme book which will be handed to all attendees from the registration desk.
Your poster must be removed by 1400 hours on Friday.
Any posters remaining after this time will not be returned to the authors but destroyed.